Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Recombinant Live Attenuated Mumps Vaccine (Genotype F) in Healthy Chinese Subjects Aged 6–59 Years
CTR20234050Phase 2Active
- Sponsor
- Qingsai Biological
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mumps vaccine, live in mumps, sponsored by Qingsai Biological. Started Dec 2023; status: active.
02
Drugs
mumps vaccine, live
03
Conditions
mumps
Beyond the preview
Go deeper on CTR20234050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234050.